|
NPS Pharmaceuticals Inc ( NPSP ) |
 |
 |
|
Healthcare
|
|
Written by Editor
|
|
Wednesday, 22 May 2013 07:44 |
NPS Pharmaceuticals Prices Public Offering of Common Stock
NPS Pharmaceuticals, Inc. (NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being sold by NPS. The gross proceeds to NPS from this offering are expected to be approximately $87.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by NPS. The offering is expected to close on or about May 24, 2013, subject to the satisfaction of customary closing conditions.
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Leerink Swann LLC are acting as lead co-managers for the offering and Oppenheimer & Co. Inc. and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.
|
|
|
Oramed Pharmaceuticals Inc ( ORMP ) |
|
|
|
Healthcare
|
|
Written by Editor
|
|
Friday, 17 May 2013 09:55 |
Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application(IND) for ORMD-0801, its oral insulin capsule.
"We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."
|
|
Theravance Inc ( THRX ) |
|
|
|
Healthcare
|
|
Written by Editor
|
|
Monday, 13 May 2013 10:12 |
Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement
Theravance to receive $1.0 billion upfront payment upon closing; Elan to receive a 21% participation interest in potential future royalty payments associated with four respiratory programs
Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, ANORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA '081), and vilanterol (VI) monotherapy. Under the terms of the agreement, Elan will make a one-time cash payment of $1.0 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from the four programs when, as and if received by Theravance.
|
|
Alexza Pharmaceuticals ( ALXA ) |
|
|
|
Healthcare
|
|
Written by Editor
|
|
Wednesday, 08 May 2013 07:56 |
Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S.
Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment
of agitation associated with schizophrenia and bipolar disorder
Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Alexza Pharmaceuticals, Inc. (ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for ADASUVE, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of ADASUVE for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.
|
|
Transition Therapeutics Inc ( TTH / TTHI ) |
|
|
|
Healthcare
|
|
Written by Editor
|
|
Tuesday, 30 April 2013 09:53 |
Transition Therapeutics Announces Results of Clinical Study of Type 2 Diabetes Drug Candidate TT-401
Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT-401 a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight.
The study enrolled diabetic patients at five dosing levels and non-diabetic obese patients at one dose level. All dosing cohorts received five doses over a five week period. Diabetic patients were on stable doses of metformin. At the end of the treatment period, TT-401-treated patients in the three highest dose groups experienced statistically significant reductions in mean fasting plasma glucose relative to placebo.
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 202 |
Stocks